SNP array analysis of tyrosine kinase inhibitor-resistant chronic myeloid leukemia identifies heterogeneous secondary genomic alterations.
about
Use of single nucleotide polymorphism array technology to improve the identification of chromosomal lesions in leukemiaChronic myeloid leukemia patients sensitive and resistant to imatinib treatment show different metabolic responsesChronic myeloid leukemia: mechanisms of blastic transformationSNP array analysis of acute promyelocytic leukemia may be of prognostic relevance and identifies a potential high risk group with recurrent deletions on chromosomal subband 1q31.3.CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia.Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells.Selection of therapy: rational decisions based on molecular events.Genetic mechanisms of chronic myeloid leukemia blastic transformation.Do we need more drugs for chronic myeloid leukemia?Different characteristics identified by single nucleotide polymorphism array analysis in leukemia suggest the need for different application strategies depending on disease category.Genome-wide high density single-nucleotide polymorphism array-based karyotyping improves detection of clonal aberrations including der(9) deletion, but does not predict treatment outcomes after imatinib therapy in chronic myeloid leukemia.SNP Array in Hematopoietic Neoplasms: A Review.Does BCR/ABL1 positive acute myeloid leukaemia exist?Protein-coding genes and long noncoding RNAs are differentially expressed in dasatinib-treated chronic myeloid leukemia patients with resistance to imatinib.Tumor suppressor gene methylation on the short arm of chromosome 1 in chronic myelogenous leukemia.
P2860
Q28390558-4842D64B-980F-4A0D-AC68-4260A9119688Q28475717-764E6774-5740-4DB9-AC83-7B4ABCDF9CEFQ33968037-BA799864-13DF-4E7C-B9D0-7F95D381D10BQ34226368-EBEB776C-1630-4ADF-A3F7-09EC24BB8001Q35030952-B1E19EA0-3BEE-4435-AF71-61443F631F44Q36850854-2C55F442-ABD6-41D0-974D-A65FB1BE0917Q37952910-8D56CC2D-92FB-4C34-9123-C98C7F55B510Q37983490-6E77BAEB-F34E-49AD-A052-A01287661BA9Q38289033-A2DD3800-7530-4963-A446-AD37A998DB8AQ38321218-0A609D23-E7A1-47CB-A830-F3E23FAA54E6Q38476431-EFB7DB24-7F1F-4628-B7A6-0B2644E4A5C0Q38947537-04D7A8B7-AF7E-4718-847F-F39C955AA575Q43782288-6D21B572-D92A-4A25-B89C-8A47E35B7B52Q46970334-9CA09C37-F707-4470-AD86-F16546F72AB8Q48303173-A33837B0-057C-4F73-8A97-DED46EC3F03F
P2860
SNP array analysis of tyrosine kinase inhibitor-resistant chronic myeloid leukemia identifies heterogeneous secondary genomic alterations.
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
SNP array analysis of tyrosine ...... secondary genomic alterations.
@ast
SNP array analysis of tyrosine ...... secondary genomic alterations.
@en
SNP array analysis of tyrosine ...... secondary genomic alterations.
@nl
type
label
SNP array analysis of tyrosine ...... secondary genomic alterations.
@ast
SNP array analysis of tyrosine ...... secondary genomic alterations.
@en
SNP array analysis of tyrosine ...... secondary genomic alterations.
@nl
prefLabel
SNP array analysis of tyrosine ...... secondary genomic alterations.
@ast
SNP array analysis of tyrosine ...... secondary genomic alterations.
@en
SNP array analysis of tyrosine ...... secondary genomic alterations.
@nl
P2093
P2860
P50
P1433
P1476
SNP array analysis of tyrosine ...... secondary genomic alterations.
@en
P2093
Alexander Kohlmann
Antonie Meixel
Daniel Nowak
H Phillip Koeffler
Markus Müschen
Max Mossner
Mi-Sook Chang
Nils H Thoennissen
Norihiko Kawamata
P2860
P304
P356
10.1182/BLOOD-2009-03-210377
P407
P577
2009-12-02T00:00:00Z